Last reviewed · How we verify
aluminum carbonate
aluminum carbonate is a aluminum carbonate drug. It is currently in unknown development for Duodenal ulcer disease, Gastric ulcer, Gastroesophageal reflux disease.
Aluminum carbonate works by neutralizing stomach acid and forming a protective barrier over the stomach lining.
Aluminum carbonate is a small molecule drug in the aluminum carbonate class, used to treat various gastrointestinal disorders. It is not clear who the current owner is or if it is FDA approved, but it is used to treat conditions such as duodenal ulcer disease, gastric ulcer, gastroesophageal reflux disease, indigestion, and peptic ulcer. The exact mechanism of action and commercial status of aluminum carbonate are unknown. As a result, key safety considerations and pharmacokinetic properties, such as half-life and bioavailability, are also unclear. Further research is needed to fully understand this medication.
At a glance
| Generic name | aluminum carbonate |
|---|---|
| Drug class | aluminum carbonate |
| Therapeutic area | Gastroenterology |
| Phase | unknown |
Mechanism of action
Imagine your stomach lining is like a delicate flower. Stomach acid can be like a strong rain that can damage the flower. Aluminum carbonate helps to neutralize the acid, creating a protective barrier that shields the flower from harm, allowing it to heal and stay healthy.
Approved indications
- Duodenal ulcer disease
- Gastric ulcer
- Gastroesophageal reflux disease
- Indigestion
- Peptic ulcer
Common side effects
Drug interactions
- cefdinir
- ciprofloxacin
- doxycycline
- enoxacin
- gatifloxacin
- itraconazole
- ketoconazole
- levofloxacin
- levothyroxine sodium
- lomefloxacin
- minocycline
- moxifloxacin
Key clinical trials
- Open-Label Placebo Treatment of Women With Premenstrual Syndrome (NA)
- Conditioned Open-label Placebos to Facilitate Opioid Reduction in Patients With Chronic Non-cancer Pain (NA)
- Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders (PHASE2)
- Microbiota Transfer Therapy for Children and Adults With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders (PHASE2)
- Paraffin Oil or Coconut Oil in Acute Aluminum Phosphide Poisoning (EARLY_PHASE1)
- PH Metry Study to Compare the Antacid Activity of Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects (PHASE1)
- Scintigraphy Study to Compare the Antireflux Activity of the Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects (PHASE1)
- A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- aluminum carbonate CI brief — competitive landscape report
- aluminum carbonate updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about aluminum carbonate
What is aluminum carbonate?
How does aluminum carbonate work?
What is aluminum carbonate used for?
What drug class is aluminum carbonate in?
What development phase is aluminum carbonate in?
Related
- Drug class: All aluminum carbonate drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Duodenal ulcer disease
- Indication: Drugs for Gastric ulcer
- Indication: Drugs for Gastroesophageal reflux disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing